Liver cancer drug trial halted early – what we know so far

NCT ID NCT06851104

Terminated Disease control Sponsor: Guangxi Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called cadonilimab in people with liver cancer who had surgery to remove their tumor but were at high risk of the cancer returning. The goal was to see if the drug could help keep the cancer away. The trial was stopped early, so the full results are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cadonilimab (AK104)
What this could lead to: If successful, this could point toward a treatment that lowers the chance of liver cancer returning after surgery.
What could go wrong: The study was terminated early, so data is limited. It is a small phase 2 trial, and the drug may cause side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, 530021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.